Robin Feldman
Robin Feldman
UC Hastings
Email confirmado em uchastings.edu
Título
Citado por
Citado por
Ano
The insufficiency of antitrust analysis for patent misuse
RC Feldman
Hastings LJ 55, 399, 2003
1482003
The America Invents Act 500: Effects of patent monetization entities on US litigation
S Jeruss, R Feldman, J Walker
Duke L. & Tech. Rev. 11, 357, 2012
1172012
Defensive leveraging in antitrust
RC Feldman
Geo. LJ 87, 2079, 1998
1111998
The open source biotechnology movement: Is it patent misuse
R Feldman
Minn. JL Sci. & Tech. 6, 117, 2004
1082004
The role of science in law
RC Feldman
Oxford University Press, 2009
1072009
Copyright and open access at the bedside
JC Newman, R Feldman
New England Journal of Medicine 365 (26), 2447-2449, 2011
832011
Do patent licensing demands mean innovation
R Feldman, MA Lemley
Iowa L. Rev. 101, 137, 2015
812015
Do analysts add value when they most can? Evidence from corporate spin‐offs
ER Feldman, SC Gilson, B Villalonga
Strategic Management Journal 35 (10), 1446-1463, 2014
69*2014
The AIA 500 Expanded: The Effects of Patent Monetization Entities
R Feldman, T Ewing, S Jeruss
UC Hastings Research Paper, 2013
682013
Rethinking Rights in Biospace
R Feldman
S. Cal. l. rev. 79, 1, 2005
662005
The giants among us
R Feldman, T Ewing
Stanford Technology Law Review 1, 2012
602012
Patent demands & startup companies: The view from the venture capital community
R Feldman
Yale JL & Tech. 16, 236, 2013
522013
Patent Trolling: Why Bio & Pharmaceuticals Are at Risk
R Feldman, W Price, II Nicholson
Stan. Tech. L. Rev. 17, 773, 2013
442013
Intellectual Property Wrongs
R Feldman
Stan. JL Bus. & Fin. 18, 250, 2012
422012
Considerations on the emerging implementation of biometric technology
R Feldman
Hastings Comm. & Ent. LJ 25, 653, 2002
422002
Whose body is it anyway-human cells and the strange effects of property and intellectual property law
R Feldman
Stan. L. Rev. 63, 1377, 2010
412010
Patent and antitrust: Differing shades of meaning
R Feldman
Va. JL & Tech. 13, 1, 2008
402008
Understanding the Incentivizing Biosimilars
J Kanter, R Feldman
Hastings LJ 64, 57, 2012
392012
Plain language patents
R Feldman
Tex. Intell. Prop. LJ 17, 289, 2008
372008
May your drug price be evergreen
R Feldman
Journal of Law and the Biosciences 5 (3), 590-647, 2018
352018
O sistema não pode efectuar a operação agora. Tente novamente mais tarde.
Artigos 1–20